MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'femara'. Sat, 03 Sep 2011 02:38:07 +0100 http://www.medworm.com/index.php?rid=5139918&cid=t_127015_112_f&fid=34971&url=http%3A%2F%2Fblog.drmalpani.com%2F2011%2F08%2Fusing-letrozole-for-ovulation-induction.html The standard medicine used for making women grow eggs ( a treatment called ovulation induction) for many years used to be clomid ( clomiphene citrate). A recent alternative to clomid is the new drug called letrozole( Femara). Letrozole, is an aromatase inhibitor, and is now being increasingly used as an alternative to clomid for inducing ovulation. The problem with clomid is that because of its antiestrogenic activity, it would cause the cervical mucus to dry up; or make the uterine lining thin. This effect would reduce fertility, so that even though ovulation induction was achieved, women would not get pregnant. Letrozole does not have the anti-estrogenic activity which clomid does, so that the uterine lining and cervical mucus with letrozole is often better than it is with clomid. The ... The Patient's Doctor blogs http://www.medworm.com/rss/comments.php?id=5139918 Fri, 19 Aug 2011 03:32:00 +0100 5139918 http://www.medworm.com/index.php?rid=4233368&cid=t_127015_136_f&fid=36032&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Flife-with-breast-cancer%2Fconsidering-my-options-without-femara%2F After writing my last blog on my decision to stop taking Femara, I wrestled all weekend with whether if that was the right thing to do. Cancer is so ominous and survivors have little recourse once treatment is over for preventing a new cancer or breast cancer metastasis. These hormonal drugs (tamoxifen, Arimidex, and Femara), are truly intended to prevent the return or spread of cancer. It is not my intention when writing about my experience to deter anyone from the protective effects these drugs have to offer — which leaves me with the dilemma of what I plan to do in place of taking them. One real option is lifestyle changes. The benefits of a low-fat diet combined with an extensive exercise regimen are well known to me. I have become soft and discouraged, though, since putting on what ... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=4233368 Mon, 06 Dec 2010 19:44:36 +0100 4233368 http://www.medworm.com/index.php?rid=4225572&cid=t_127015_136_f&fid=36032&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Flife-with-breast-cancer%2Fmy-deep-dark-femara-secret%2F Last January, my oncologist gave me a prescription for Femara because my five-year course with tamoxifen had finished. Research shows maximum benefits from hormonal treatment if tamoxifen is followed by an aromatase inhibitor like Arimidex or Femara for five years. I tried Arimidex in 2006 and wrote about how I had to stop because the side effects were so debilitating. So I initially put off taking it and then later blogged about the prescription still stuck to my fridge. Comments from many of you tried to ease my concerns and encouraged me to take it. So I agreed I would. I need to come clean. Until I had the bone cancer scare that I wrote about last week in my blog about pain and breast cancer, I wasn’t taking Femara. I had good intentions — really I did — mostly because of concern... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=4225572 Fri, 03 Dec 2010 20:24:16 +0100 4225572 http://www.medworm.com/index.php?rid=3142831&cid=t_127015_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FYDsWID7KjMQ%2F In an attempt to dissect the profitability of big drugs - and gauge their contribution to a drugmaker’s overall profit and loss - Sanford Bernstein analyst Tim Anderson recently crunched some numbers showing, among other things, that roughly 30 of the 52 drugs he examined have pretax margins that are 70 percent or higher. This compares to the average drug company pretax margin of about 32 percent. His point: a big drug may only account for 10 percent of a company’s total sales, but its contribution to pretax profits could be twice as large. And as patent cliffs loom, this is important. Here are the drugs offering the biggest payback: 1 - Effexor (Pfizer) 87 percent 2 - Arimidex (AstraZeneca) 85 percent 3 - Femara (Novartis) 84 percent 4 - Detrol (Pfizer) 84 percent 5 - Gemzar ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3142831 Tue, 05 Jan 2010 14:44:08 +0100 3142831 http://www.medworm.com/index.php?rid=2212648&cid=t_127015_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F24%2Feuropean-researchers-find-estrogen-receptor-gene-amplification-occurs-rarely-in-ovarian-cancer%2F “… ESR1 [gene] amplification is an uncommon mechanism for estrogen receptor overexpression in ovarian cancer occurring in about 2.1% of the total number of ovarian cancers. In general, this frequency parallels the fraction of ovarian cancers reported to show complete response to antiestrogenic [anti-hormonal] therapies. Given the strong predictive power of ESR1 [gene] amplification for [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2212648 Tue, 24 Feb 2009 23:03:08 +0100 2212648 http://www.medworm.com/index.php?rid=1727798&cid=t_127015_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2008%2F08%2F18%2Fworking-smarter-not-harder-anti-estrogen-therapy-to-battle-recurrent-ovarian-cancer%2F The Gynecologic Oncology department of the University of Texas, M.D. Anderson Cancer Center took a page out of the breast cancer treatment “playbook,” and conducted a single institution Phase II clinical trial using letrozole (Femara®) to treat recurrent, platinum and taxane resistant, high-grade cancer of the ovary and peritoneum. …The trial investigators concluded that 26% [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=1727798 Tue, 19 Aug 2008 03:28:31 +0100 1727798 http://www.medworm.com/index.php?rid=897083&cid=t_127015_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F160791153%2F The country’s National Health Security Office is renewing its threat to issue compulsory licenses on at least three cancer meds if negoiations with drugmakers don’t yield lower prices, The Bangkok Post reports. The drugs that could be affected include Genentech’s Tarceva; Taxotere from Sanofi-Aventis; and Novartis’ Femara. The meds are used to treat various cancers, ranging from tumors, breast and lung cancer. Thailand’s Public Health Minister, Mongkol Na Songkhla confirmed the government will carefully and thoroughly consider its move to effectively “break the patents” of the cancer med, but stressed the move was necessary if the government wanted to ensure broader access to necessary drugs. “To apply the CL is Thailand’s last resort,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=897083 Mon, 24 Sep 2007 21:42:50 +0100 897083 http://www.medworm.com/index.php?rid=692346&cid=t_127015_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F06%2F23%2Ffemara-and-ovarian-cancer%2F Filed under: Drug, Ovarian Cancer, Clinical Trials, ResearchFemara (letrozole) provides both anticancer responses and disease stabilization in a significant number of patients with recurrent, estrogen receptor positive ovarian cancer. The results of the study were published in Clinical Cancer Research. Femara blocks levels of estrogen in the body, ultimately reducing or preventing growth of estrogen positive cancer cells. Femara has been demonstrated to be effective for estrogen positive breast cancer, but has not yet had a clear influence in women with ovarian cancer. Forty two patients were part of a clinical trial to evaluate the effectiveness of Femara. At three months, 42 percent of patients achieved disease stabilization and 9 percent achieved a regression of their disease. At over s... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=692346 Sat, 23 Jun 2007 04:00:00 +0100 692346